1. BIOQUAL reported revenue of $48.87 million for 2024. 2. Company faced a net loss of $1.05 million in 2024. 3. Projected revenue increase to $58.59 million in 2025. 4. Forward-looking statements emphasize revenue risks and uncertainties. 5. The company depends on government contracts for future growth.
The projected revenue increase and reduced losses may attract investors, similar to past recoveries in biotech companies after positive outlooks.
The financial performance and projections could lead to increased investor interest, influencing long-term share price positively.
The forward-looking revenue projections suggest a longer timeframe for observing impact, akin to trends seen in biotech recoveries following positive financial outlooks.
BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):
|
|
2025 |
|
|
2024 |
Revenue |
$ |
48,867,753 |
|
$ |
58,590,949 |
(Loss) Income Before Income Tax |
$ |
(1,896,010 |
) |
$ |
476,447 |
Net (Loss) Income |
$ |
(1,048,154 |
) |
$ |
483,481 |
Basic Earnings per Share of Common Stock |
$ |
(1.17 |
) |
$ |
.54 |
Diluted Earnings per Share of Common Stock |
$ |
(1.17 |
) |
$ |
.54 |
Weighted Average |
|
|
|
|
|
Number of Shares Outstanding |
|
|
|
|
|
For Basic Earnings Per Share |
|
894,416 |
|
|
894,416 |
Weighted Average |
|
|
|
|
|
Number of Shares Outstanding |
|
|
|
|
|
For Diluted Earnings Per Share |
|
894,416 |
|
|
894,416 |
Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. The forward-looking statements are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including risks relating to the ability to continue to extend current government contracts; the Company's ability to obtain new government and commercial contracts; continued demand for the use of animal models in scientific research; the Company's ability to obtain sufficient numbers of animal models; the availability of adequate numbers of employees; the Company's ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company's contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250919294179/en/
Hanne E. Andersen, Ph.D.
President and CSO
(240-404-7654)
handersen@bioqual.com